ROSEMARIE SCHMANDT to Cell Proliferation
This is a "connection" page, showing publications ROSEMARIE SCHMANDT has written about Cell Proliferation.
Connection Strength
0.151
-
ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun. 2020 07 15; 11(1):3546.
Score: 0.018
-
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
Score: 0.014
-
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29; 7:11150.
Score: 0.014
-
Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer. 2014 Nov 15; 120(22):3457-68.
Score: 0.012
-
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecol Oncol. 2014 Apr; 133(1):83-9.
Score: 0.012
-
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013 Dec; 12(12):2847-56.
Score: 0.011
-
Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 2013 Jul; 209(1):24.e1-24.e12.
Score: 0.011
-
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.
Score: 0.011
-
Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
Score: 0.009
-
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
Score: 0.008
-
Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8.
Score: 0.008
-
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol. 2008 Aug; 2(2):164-81.
Score: 0.008
-
Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene. 2007 Apr 19; 26(18):2574-84.
Score: 0.007
-
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
Score: 0.007